ProQR Therapeutics (PRQR) Non-Current Debt (2016 - 2023)

ProQR Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $4.6 million for Q4 2023.

• In Q4 2023, Non-Current Debt rose 5.98% year-over-year to $4.6 million; the TTM figure through Dec 2023 stood at $4.6 million (up 5.98% YoY), while the FY2023 annual figure was $4.6 million, up 5.98% from the prior year.
• Non-Current Debt came in at $4.6 million for Q4 2023 at ProQR Therapeutics, up from $4.4 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $45.0 million in Q4 2021 to a low of $4.4 million in Q4 2022.
• A 5-year average of $17.5 million and a median of $14.1 million in 2019 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 133.03% in 2021 and slumped 90.31% in 2022, its largest moves.
• ProQR Therapeutics' Non-Current Debt stood at $14.1 million in 2019, then surged by 37.21% to $19.3 million in 2020, then jumped by 133.03% to $45.0 million in 2021, then sank by 90.31% to $4.4 million in 2022, then rose by 5.98% to $4.6 million in 2023.
• According to Business Quant data, Non-Current Debt over the past three periods registered $4.6 million, $4.4 million, and $45.0 million for Q4 2023, Q4 2022, and Q4 2021 respectively.

Peer Comparison